

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
GRASSBERGER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/003514

FILED: 2 APRIL 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: PHARMACEUTICAL COMPOSITION COMPRISING A MACROLIDE
IMMUNOMODULATOR

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/003514, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614

Date: 9/23/05

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

PD/4-32805A

APPLICATION NO.

Not Yet Known

APPLICANT

GRASSBERGER ET AL.

FILING DATE

Herewith

Group

10/550356

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	0 867 438	9/30/98	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	1 074 263	2/7/01	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	1 273 288	1/8/03	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	03/035068	5/1/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	03/057249	7/17/02	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Chamlin et al., "Ceramide-Dominant Barrier Repair Lipids Alleviate Childhood Atopic Dermatitis: Changes in Barrier Function Provide a Sensitive Indicator of Disease Activity", J. Am. Acad. Dermatol., Vol. 47, No. 2 (2002).
	AS	Rudikoff, "Commentary: Eczema", Clinics in Dermatology, Vol. 21, No. 2, pp. 93-94 (2003).
	AT	Rudikoff et al., "Atopic Dermatitis", Lancet, Vol. 351 (1998).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.